Long Shortz with Arovella Therapeutics: IP and clinical milestones drive next phase for ALA-101

Tylah Tully chats with Arovella Therapeutics (ASX:ALA) CEO and managing director Dr Michael Baker who explains how the company’s soon-to-be-granted US patent for its CAR-iNKT cell therapy platform is a major milestone, strengthening intellectual property protection in a key global market.

The patent covers Arovella’s manufacturing process, underpinning its efforts to treat cancers ranging from lymphomas and leukemias to solid tumours.

The US is a critical focus for Arovella as it prepares to submit an Investigational New Drug (IND) application to the FDA, aiming to begin its first-in-human trial of ALA-101 in Australia shortly after approval.

Beyond ALA-101, the company is advancing its second program ALA-105 targeting gastric and potentially pancreatic cancers and expects to release data and updates on commercial collaborations, including its work with Baylor College of Medicine, over the coming months.

This video was developed in collaboration with Arovella Therapeutics, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.